Search results
Small Business - The Andalusia Star-News | The Andalusia Star-News
The Andalusia Star-News· 5 days agoGenFleet Therapeutics Announces Efficacy & Safety Result from Phase II Trial for First-line NSCLC Treatment in KROCUS Study, fulzerasib (KRAS G12C Inhibitor) in Combination with cetuximab, in a Late-breaking Abstract at the Oral Presentation of 2024
Ibram X. Kendi Faces a Reckoning of His Own
New York Times· 3 days agoIbram X. Kendi has a notebook that prompts him, on every other page, to write down “Things to be grateful for.” Tenure at Boston University, where Martin...
Lack of insurance may prevent Americans from accessing best cancer drugs
UPI· 4 days agoA cutting-edge class of drugs is saving and extending the lives of cancer patients. But the drugs,...
'Disturbing' surge in young cancers may be linked to gut health, say experts
Daily Express· 5 days agoUnhealthy lifestyles, an obesity epidemic and poor gut health are feared to be fuelling a...
ASCO24: Tagrisso in the spotlight, Caribou’s adjustment and Lilly’s KRAS competitor
BioPharma Dive via Yahoo Finance· 4 days agoAstraZeneca’s therapy could see wider use after ASCO data. Elsewhere, Caribou sought to explain an...
Landmark Blood-Based AI Lung Cancer Screening Test Study Results Published in Cancer Discovery
Tehachapi News· 4 days agoThe transformative approach to genomic sequencing yields the first validated high-sensitivity lung cancer screening test that could close gaps in screening. BALTIMORE and ...
Small Business - The Roanoke-Chowan News-Herald | The Roanoke-Chowan News-Herald
Roanoke-Chowan News-Herald· 3 days agoProgress in the LIBERATE trial was presented at the American Transplant Congress today London, UK– June 4, 2024 – Quell Therapeutics Ltd (“Quell”), a leader in developing engineered T-regulatory (Treg) cell therapies for serious medical
